Suppliers / Hangzhou Zhongmeihuadong Pharmaceutical Jiangdong

Hangzhou Zhongmeihuadong Pharmaceutical Jiangdong

China 1 employees Updated 9 July 2026

Hangzhou Zhongmeihuadong Pharmaceutical Jiangdong is an API manufacturer based in China. It holds 2 active US drug master files across a filed portfolio of 2 molecules. Its GMP standing is certified by US FDA. Its most recent recorded inspection, by US FDA, closed on 9 August 2024 as NAI.

2
active US DMFs
0
valid CEPs
1
registered plants 1 with an FDA FEI number
0
filings across 0 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
1 of 1 confirmed
Inspections
1 of 1 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026.

Inspection history

  • 9 August 2024 NAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
China, China 3017308146

What they file, and where

Molecule Regulators Docs
Acarbose US FDA 1
Semaglutide US FDA 1

Also appears on these molecule pages

Acarbose API Semaglutide API

Filings and GMP by regulator

Regulator Filings GMP certificates
US FDA None 1

Questions about Hangzhou Zhongmeihuadong Pharmaceutical Jiangdong

Does Hangzhou Zhongmeihuadong Pharmaceutical Jiangdong hold a US DMF or a CEP?
Hangzhou Zhongmeihuadong Pharmaceutical Jiangdong holds 2 active US drug master files. A drug master file is a submission to the FDA describing how an ingredient is made; a CEP is the EDQM's certificate that the substance meets its European Pharmacopoeia monograph. Both are filings rather than approvals.
Is Hangzhou Zhongmeihuadong Pharmaceutical Jiangdong FDA-registered?
One site operated by Hangzhou Zhongmeihuadong Pharmaceutical Jiangdong carries an FDA establishment identifier (FEI), which means it is registered with the FDA as a drug establishment. Registration is not the same as approval or inspection clearance.
How did Hangzhou Zhongmeihuadong Pharmaceutical Jiangdong's last inspection go?
The most recent inspection on record closed on 9 August 2024 as NAI (No Action Indicated: nothing objectionable was found). 1 inspection is on file.
Where does Hangzhou Zhongmeihuadong Pharmaceutical Jiangdong manufacture?
1 registered site is on record, in China (China). Every site is listed on this page with the register it came from.
What does Hangzhou Zhongmeihuadong Pharmaceutical Jiangdong make?
2 molecules are on record against Hangzhou Zhongmeihuadong Pharmaceutical Jiangdong, including Acarbose and Semaglutide. Each links through to that molecule's full manufacturer list.
Which regulators recognise Hangzhou Zhongmeihuadong Pharmaceutical Jiangdong's GMP?
Current GMP certificates are on record from US FDA. GMP recognition covers the manufacturing site, separately from any filing on the substance itself.

Answered from this company's own record. Where a register holds nothing, the question is not asked rather than answered with a zero. How we count our figures.

Comparing suppliers?

Choose your molecules and target markets. Hangzhou Zhongmeihuadong Pharmaceutical Jiangdong comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • The most recent inspection outcome was NAI, on 9 August 2024.

Comparable suppliers

Dr Reddy's Laboratories shares 1 molecule Zydus Lifesciences shares 1 molecule Changzhou Pharmaceutical Factory shares 1 molecule Biocon shares 1 molecule Piramal Pharma shares 1 molecule

Ranked by shared active ingredients where we have them, otherwise by country and comparable credentials.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
EudraGMDP and national regulators
GMP certificates